Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer, Roche, AstraZeneca: Emerging Markets Earnings Roundup (Part 3)

This article was originally published in PharmAsia News

Executive Summary

Year-end and Q4 pharma earnings results emphasized emerging markets as one positive in a challenging environment posed by U.S. healthcare reform and European price cuts and austerity measures. Pharma companies stressed cost-cutting actions such as restructuring their businesses and closing facilities in the U.S. and Europe, while simultaneously discussing increased resource allocation for Asia and other emerging markets.

You may also be interested in...



Lacking Guidelines, HER2 Testing Brings Challenges To Breast Cancer Treatment In China

In a recent report, Kantar Health takes a deep dive into China’s breast cancer market, where cost considerations play a larger role than in the West.

Lacking Guidelines, HER2 Testing Brings Challenges To Breast Cancer Treatment In China

In a recent report, Kantar Health takes a deep dive into China’s breast cancer market, where cost considerations play a larger role than in the West.

Pfizer Steams Ahead Despite Price Cuts; Merck Ramps Up In China: Emerging Markets Earnings Round Up (Part 3)

Related Content

UsernamePublicRestriction

Register

SC077168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel